menu
    • menu
    [{"orgOrder":0,"company":"OmniaBio","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OmniaBio \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"OmniaBio \/ Catamaran Bio"},{"orgOrder":0,"company":"OmniaBio","sponsor":"Somite Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"SMT-M01","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OmniaBio \/ Somite Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"OmniaBio \/ Somite Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by OmniaBio

    Menu

    OmniaBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OmniaBio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            OmniaBio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SMT-M01

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Somite Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Somite and OmniaBio Partner To Advance Somite's Cell Therapy Program

                            Details : The collaboration aims to manufacture and produce SMT-M01, Somite's flagship program, which is being evaluated in early-stage clinical studies for treating patients with Duchenne muscular dystrophy.

                            Brand Name : SMT-M01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : SMT-M01

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Somite Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OmniaBio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            OmniaBio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Catamaran Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Catamaran Bio Selects Omniabio As Partner To Develop And Manufacture Allogeneic CAR-NK Cell Therapies

                            Details : The partnership will enable the development and manufacturing of Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.

                            Brand Name : Undislcosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : CAR-NK Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Catamaran Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth